Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and ... Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. Mehr anzeigen
Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes PR Newswire WILMINGTON, Del. and WALTHAM, Mass., Jan. 15, 2025...
Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire WALTHAM, Mass., Jan. 13, 2025 – Launched Revuforj®...
Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 7, 2025 NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder...
Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference PR Newswire WALTHAM, Mass., Jan. 7, 2025 WALTHAM, Mass., Jan. 7, 2025 /PRNewswire/ -- Syndax Pharmaceuticals...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., Jan. 3, 2025 WALTHAM, Mass., Jan. 3, 2025 /PRNewswire/ -- Syndax Pharmaceuticals...
Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial PR Newswire WALTHAM, Mass...
Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting PR Newswire WALTHAM...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., Dec. 3, 2024 WALTHAM, Mass., Dec. 3, 2024 /PRNewswire/ -- Syndax Pharmaceuticals...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.71 | -5.17115804807 | 13.73 | 13.92 | 12.06 | 1625140 | 12.84262349 | CS |
| 4 | 0.17 | 1.32295719844 | 12.85 | 14.65 | 12.06 | 2524823 | 13.2372231 | CS |
| 12 | -6.2 | -32.2580645161 | 19.22 | 22.5 | 12.06 | 2251718 | 15.18077664 | CS |
| 26 | -11.43 | -46.7484662577 | 24.45 | 25.07 | 12.06 | 1535774 | 16.84392062 | CS |
| 52 | -8.98 | -40.8181818182 | 22 | 25.34 | 12.06 | 1316965 | 18.80327612 | CS |
| 156 | -4.71 | -26.565143824 | 17.73 | 29.86 | 11.215 | 1063060 | 19.05397139 | CS |
| 260 | 4.23 | 48.1228668942 | 8.79 | 29.86 | 6.32 | 874566 | 18.83735328 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
